tirzepatide and osteoporosis Tirzepatide, a dual GLP-1 GIP receptor agonist, promotes bone loss in obese mice via gut microbial-related metabolites New Webinar: There are many

Don't take two doses to make up for the missed one

It does not incur the so-called yo-yo phenomenon

The Nasal Spray Nuance: More Than Just Temperature Creating a nasal spray introduces even more variables that make proper storage critical

When seeking cellulite treatment, its important to have realistic expectations: whichever method you choose, expect it to reduce, but not fully erase, cellulite

Contraindication Screening Personal or family history of medullary thyroid carcinoma, MEN2 syndrome, prior pancreatitis, and severe gastroparesis are absolute or relative contraindications to GLP-1 therapy per the FDA label and Endocrine Society guidance 23

C., Mitby P., Occhiogrosso G., Qin J., Heller G., et al